Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Normal Donors

Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study

Summary:

Healthy allogeneic donors, who were treated with G-CSF and underwent peripheral blood haematopoietic precursor collection at our Institution, were enrolled in a short- and long-term haematological surveillance protocol for a 5–7-year period. To date, 94 donors have been assessed with a mean follow-up of 30 months (4–84); for 30 subjects, the follow-up is 48 months. During G-CSF administration, 23/94 donors showed a significant platelet count decrease from the baseline. Pre-apheresis platelet decrement correlated with the total G-CSF dose administered, baseline platelet level and donor age. Normal platelet counts returned within 4–8 months. PMN and/or lymphocyte lower values were observed in 55/94 donors 2 weeks after G-CSF administration, with mean drops from the baseline of 40 and 36% for PMN and lymphocytes, respectively. The PMN decrease correlated inversely with donor age, as younger donors were more affected than older ones, whereas the lymphocyte decrease correlated directly with the total blood volumes processed in the apheresis courses, in particular for donors subjected to large volume leukaphereses. Long-term observation showed moderate neutrophil reduction (25% count drop from the baseline) in four of the 30 donors observed for four years or more. 14 donors showed persistent, slight lymphocytopenia (mean drop of 13%) until the third year, with recovery in the fourth year of follow-up.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Anderlini P, Przepiorka D, Champlin R, Korbling M . Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819–2825.

    CAS  Google Scholar 

  2. Cesaro S, Marson P, Gazzola MV et al. The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation. Haematologica 2002; 87: 35–41.

    PubMed  Google Scholar 

  3. Korbling M, Champlin R . Peripheral blood progenitor stem transplantation: a replacement for marrow auto or allografts. Stem Cells 1996; 14: 185–195.

    Article  CAS  Google Scholar 

  4. Kaplinsky C, Trakhtenbrot L, Hardan I et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.

    Article  CAS  Google Scholar 

  5. Makita K, Ohta K, Mugitani A et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661–665.

    Article  CAS  Google Scholar 

  6. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590–595.

    Article  CAS  Google Scholar 

  7. Hilbe W, Nussbaumer W, Bonatti H et al. Unusual adverse effects following peripheral blood-stem cell (PBSC) mobilization using granulocyte colony-stimulating factor (G-CSF) in healthy donors. Bone Marrow Transplant 2000; 26: 811–813.

    Article  CAS  Google Scholar 

  8. Adkins DR . Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor. J Clin Oncol 1998; 16: 812–813.

    Article  CAS  Google Scholar 

  9. Stroncek D, Shawker T, Follmann D, Leitman SF . G-CSF induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609–613.

    Article  CAS  Google Scholar 

  10. Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432–1433.

    Article  CAS  Google Scholar 

  11. Cavallaro AM, Lilleby K, Majolino I et al. Three to six years of follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.

    Article  CAS  Google Scholar 

  12. Stroncek DF, Clay ME, Herr G et al. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997; 37: 304–308.

    Article  CAS  Google Scholar 

  13. Anderlini P, Korbling M, Dale D et al. Allogeneic blood stem cell transplantation: consideration for donors. Blood 1997; 90: 903–908.

    CAS  Google Scholar 

  14. Stroncek D, McCullough J . Policies and procedures for the establishment of an allogeneic blood stem cell collection programme. Transfusion Med 1997; 7: 77–87.

    Article  CAS  Google Scholar 

  15. Executive Committee of the World Marrrow Donor Association: Bone marrow transplant using volunteers donors. Recommendation and requirements for a standardized practice throughout the world. Bone Marrow Transplant 1992; 10: 287–293.

  16. GITMO, IBMDR, SidE, SIE. Linee guida per la raccolta delle cellule staminali ai fini di un trapianto allogenico di midollo osseo. SIMTI servizi 2001.

  17. Anderlini P, Przepiorka D, Seong D et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996; 94: 155–158.

    Article  CAS  Google Scholar 

  18. Stroncek DF, Clay ME, Petzold ML et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and the collection of peripheral blood stem cells. Transfusion 1996; 36: 601–610.

    Article  CAS  Google Scholar 

  19. Martinez C, Urbano-Ispizua A, Rozman M et al. Effects of short-term administration of G-CSF (Filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Bone Marrow Transplant 1999; 23: 15–19.

    Article  CAS  Google Scholar 

  20. Rutella S, Rumi C, Pierelli L et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol 2000; 28: 164–168.

    Google Scholar 

  21. Nagler A, Korenstein-Ilan A, Amiel A, Avivi A . Granulocyte-colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R Conte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tassi, C., Tazzari, P., Bonifazi, F. et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 36, 289–294 (2005). https://doi.org/10.1038/sj.bmt.1705066

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705066

Keywords

This article is cited by

Search

Quick links